GlaxoSmithKline Plc (GSK)

40.20
0.10 0.25
NYSE : Health Technology
Prev Close 40.30
Open 40.28
Day Low/High 40.11 / 40.34
52 Wk Low/High 34.52 / 42.36
Volume 1.44M
Avg Volume 2.35M
Exchange NYSE
Shares Outstanding 2.48B
Market Cap 97.68B
EPS 0.80
P/E Ratio 22.91
Div & Yield 2.15 (5.44%)

Latest News

GlaxoSmithKline Gets a Boost

GlaxoSmithKline Gets a Boost

Drugmaker's charts show positive signs ahead.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ELON, EVRI, GSK, ITGR, MRAM, NPO, PLNT, QIWI, RUN, SFM, WIT Downgrades: ALEX, CVM, METC, SBGI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Gilead's Earnings Fail to Impress

Gilead's Earnings Fail to Impress

The company is losing sales aggressively as it fails to create any business substantial enough to make up for the shrinking sales in its Hepatitis C drugs.

ViiV Healthcare Announces SWORD 100-week Data For Juluca (dolutegravir/rilpivirine) At AIDS 2018

ViiV Healthcare Announces SWORD 100-week Data For Juluca (dolutegravir/rilpivirine) At AIDS 2018

ViiV Healthcare today presented 100-week results from its phase III programme evaluating the safety and efficacy of switching virologically-suppressed people living with HIV (PLHIV) from a three or four-drug antiretroviral regimen to a 2-drug regimen of...

ViiV Healthcare Presents Phase III Data At AIDS 2018 From Landmark GEMINI Studies Showing Two-Drug Regimen Of Dolutegravir And Lamivudine Has Similar Efficacy To A Three-Drug Regimen In Treatment Naïve HIV Patients, With No Emergence Of Resistance

ViiV Healthcare Presents Phase III Data At AIDS 2018 From Landmark GEMINI Studies Showing Two-Drug Regimen Of Dolutegravir And Lamivudine Has Similar Efficacy To A Three-Drug Regimen In Treatment Naïve HIV Patients, With No Emergence Of Resistance

ViiV Healthcare today presented at the 22 nd International AIDS conference in Amsterdam 48-week results from the phase III GEMINI 1 & 2 studies, assessing the safety and efficacy of a two-drug regimen (2DR) of dolutegravir (DTG) and lamivudine (3TC)...

GSK Shares Climb as Board Is Said to Mull Breakup of Pharma Giant

GSK Shares Climb as Board Is Said to Mull Breakup of Pharma Giant

The pharmaceutical giant's American depository receipts jumped on the heels of a report that the company's chairman is mulling a breakup of the firm.

GlaxoSmithKline Is a Healthy Choice for Income Investors

The pharmaceuticals giant yields 4.85% and has lots of things going for it.

Elliott Tackles AC Milan After Chinese Investors Falter; Pfizer Eyes Reorg-ICYMI

Elliott Tackles AC Milan After Chinese Investors Falter; Pfizer Eyes Reorg-ICYMI

Here's what you need to know now for Wednesday, July 11.

Pfizer Announces Big Reorganization As It Continues Trying to Sell Consumer Biz

Pfizer Announces Big Reorganization As It Continues Trying to Sell Consumer Biz

The changes will take effect at the start of 2019.

Creates Act Clears Committee Vote, Could Ease Way for Generic Drugmakers

Creates Act Clears Committee Vote, Could Ease Way for Generic Drugmakers

While the CREATES ACT passed out of committee in the Senate, Senator Orrin Hatch, who helped pave the way for generic drugs in the U.S,,voted against the measure.

Mylan Slumps in After-Hours Trading on Generic Advair Update

Mylan Slumps in After-Hours Trading on Generic Advair Update

The drugmaker says the FDA will issue a complete response letter on June 27.

GSK Submits Regulatory Application In Japan For Once-Daily Single Inhaler Triple Therapy FF/UMEC/VI For Patients With COPD

GSK Submits Regulatory Application In Japan For Once-Daily Single Inhaler Triple Therapy FF/UMEC/VI For Patients With COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for once-daily fluticasone furoate/umeclidinium/vilanterol...

Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

President Trump's appetite for TV and ratings is legendary and now the administration wants to require drug company TV ads to include the list price of prescription drugs.

20 Top Stocks From Around the World With an Average 25% Upside Potential

20 Top Stocks From Around the World With an Average 25% Upside Potential

In this market, picking the right stocks is paramount. Here is a tidy list of top ideas from the strategy team at HSBC.

What to Expect From Allergan, Aetna, Merck and Pfizer's Earnings Next Week

What to Expect From Allergan, Aetna, Merck and Pfizer's Earnings Next Week

The drugmakers and health insurer are preparing to unveil first-quarter numbers.

Walgreens, Arena Pharma, Dominion Energy: 'Mad Money' Lightning Round

Walgreens, Arena Pharma, Dominion Energy: 'Mad Money' Lightning Round

Jim Cramer focuses on Walgreens Boots Alliance, Arena Pharmaceutical, Dominion Energy, Tower Semiconductor, Idexx, LexinFintech Holdings and more.

FANG, Tariffs, Trade: Cramer's 'Mad Money' Recap (Thursday 4/26/18)

FANG, Tariffs, Trade: Cramer's 'Mad Money' Recap (Thursday 4/26/18)

It's not all about the bond market, says Jim Cramer. The central issues here are trade, tariffs and most important, the stocks themselves, like Facebook and Amazon.

Innoviva Is Attractive Play in Biotech

Innoviva Is Attractive Play in Biotech

Strong balance sheet and royalties are big positives for Innoviva.

The Global Stock Market Rout Spreads Across the World

The Global Stock Market Rout Spreads Across the World

Global stocks are on the defensive Wednesday, pulling U.S. futures and European shares lower, as investor re-set expectations for corporate profits in the face of rising investment and input costs.

Once-Daily Trelegy Ellipta Gains Expanded Indication In The US For The Treatment Of Patients With COPD

Once-Daily Trelegy Ellipta Gains Expanded Indication In The US For The Treatment Of Patients With COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI'), which...

Fate of Pfizer Unit in Spotlight After Merck Sells Consumer Business

Fate of Pfizer Unit in Spotlight After Merck Sells Consumer Business

Procter & Gamble, which is buying the Merck unit, was previously reported to be in talks to acquire Pfizer's consumer healthcare business.

Mylan's Stock Gets Bump After Investor Day

Mylan's Stock Gets Bump After Investor Day

Following Wednesday's event, Leerink analyst Ami Fadia said she is 'incrementally more positive' on the drugmaker's pipeline and diversified business model and moved her rating to outperform.

Novartis Agrees to Buy AveXis in $8.7 Billion Deal

Novartis Agrees to Buy AveXis in $8.7 Billion Deal

The acquisition is a big move for Novartis CEO Vas Narasimhan, who took the helm in February.

Blackberry, SkyWest, Apache: 'Mad Money' Lightning Round

Blackberry, SkyWest, Apache: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Blackberry, SkyWest, Apache, Philip Morris International, PetMed Express, Iron Mountain, Novartis.

Behind the Selloff: Cramer's 'Mad Money' Recap (Friday 4/6/18)

Behind the Selloff: Cramer's 'Mad Money' Recap (Friday 4/6/18)

This market is deceptive and you need to recognize your sense of timing is not infallible. So, adjust your scales and get ready for next week, says Jim Cramer.

If Stocks Don't Pop on All This Deals News Investors Better Look Out Below

If Stocks Don't Pop on All This Deals News Investors Better Look Out Below

M&A activity kicks into high gear going into the final days of the first quarter. If the broader stock market doesn't pop on this news, it would be a red flag.

4 Strong Buy Biotech Stocks Poised to Explode

4 Strong Buy Biotech Stocks Poised to Explode

Here comes the growth. These four strong buy biotech stocks are potentially on the cusp of very big growth.

The Dow Plunges Into the Close of Trading on Tuesday

The Dow Plunges Into the Close of Trading on Tuesday

Cooling tensions with China aren't enough to save investors on Tuesday.

TheStreet Quant Rating: B- (Buy)